Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

6 recruiting

Enrollment Performance

Analytics

Phase 1
6(85.7%)
Early Phase 1
1(14.3%)
7Total
Phase 1(6)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT06492863Phase 1Recruiting

Gene Therapy(FT-003) for Wet AMD

Role: lead

NCT06492850Phase 1Recruiting

Gene Therapy for RPGR Gene Mutation-associated X-linked Retinitis Pigmentosa

Role: lead

NCT06492876Phase 1Recruiting

Gene Therapy for DME

Role: lead

NCT05916391Phase 1Recruiting

Gene Therapy for Diabetic Macular Edema

Role: lead

NCT05874310Early Phase 1Recruiting

Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa

Role: lead

NCT05858983Phase 1Recruiting

Gene Therapy in Subjects With Biallelic RPE65 Mutation-associated Retinal Dystrophy

Role: lead

NCT05611424Phase 1Not Yet Recruiting

Gene Therapy for Wet AMD

Role: lead

All 7 trials loaded